{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:19:09Z","timestamp":1792819149140,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00259-025-07352-6","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:43:33Z","timestamp":1748321013000},"page":"4860-4869","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multitracer comparison of gold standard PSMA-PET\/CT with 68Ga-FAPI and 18F-FDG in high-risk prostate cancer: a proof-of-concept study"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3634-9541","authenticated-orcid":false,"given":"Osama","family":"Mahmoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"P\u00fcllen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Umutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Szarvas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Bayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris A.","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulham","family":"Al-Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Berliner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"issue":"7","key":"7352_CR1","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1200\/JCO.2009.26.0133","volume":"28","author":"MR Cooperberg","year":"2010","unstructured":"Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7):1117\u201323.","journal-title":"J Clin Oncol"},{"issue":"3","key":"7352_CR2","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.juro.2010.10.057","volume":"185","author":"SE Eggener","year":"2011","unstructured":"Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011;185(3):869\u201375.","journal-title":"J Urol"},{"issue":"1","key":"7352_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.eururo.2012.08.001","volume":"63","author":"JR Rider","year":"2013","unstructured":"Rider JR, Sandin F, Andr\u00e9n O, Wiklund P, Hugosson J, Stattin P. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol. 2013;63(1):88\u201396.","journal-title":"Eur Urol"},{"issue":"3","key":"7352_CR4","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41391-020-00298-w","volume":"24","author":"EJ Bass","year":"2021","unstructured":"Bass EJ, Pantovic A, Connor M, Gabe R, Padhani AR, Rockall A, et al. A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk. Prostate Cancer Prostatic Dis. 2021;24(3):596\u2013611.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"7352_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.juro.2014.07.098","volume":"193","author":"JP Radtke","year":"2015","unstructured":"Radtke JP, Kuru TH, Boxler S, Alt CD, Popeneciu IV, Huettenbrink C, et al. Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance. J Urol. 2015;193(1):87\u201394.","journal-title":"J Urol"},{"issue":"6","key":"7352_CR6","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1007\/s00330-023-10436-2","volume":"34","author":"J Ma","year":"2024","unstructured":"Ma J, Yang Q, Ye X, Xu W, Chang Y, Chen R, et al. Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis. Eur Radiol. 2024;34(6):4017\u201337.","journal-title":"Eur Radiol"},{"key":"7352_CR7","doi-asserted-by":"crossref","unstructured":"Zhao Y, Simpson BS, Morka N, Freeman A, Kirkham A, Kelly D, et al. Comparison of multiparametric magnetic resonance imaging with prostate-Specific membrane antigen Positron-Emission tomography imaging in primary prostate cancer diagnosis: a systematic review and meta-analysis. Cancers (Basel). 2022;14(14):3497.","DOI":"10.3390\/cancers14143497"},{"issue":"10231","key":"7352_CR8","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316.","journal-title":"Lancet"},{"issue":"2","key":"7352_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86(2):148\u201363.","journal-title":"Eur Urol"},{"key":"7352_CR10","doi-asserted-by":"publisher","first-page":"1544208","DOI":"10.1155\/2021\/1544208","volume":"2021","author":"S McGeorge","year":"2021","unstructured":"McGeorge S, Kwok M, Jiang A, Emmett L, Pattison DA, Thomas PA, et al. Dual-Tracer Positron-Emission tomography using prostate-Specific membrane antigen and Fluorodeoxyglucose for staging of prostate cancer: A systematic review. Adv Urol. 2021;2021:1544208.","journal-title":"Adv Urol"},{"issue":"4","key":"7352_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrurol.2016.26","volume":"13","author":"T Maurer","year":"2016","unstructured":"Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13(4):226\u201335.","journal-title":"Nat Rev Urol"},{"issue":"11","key":"7352_CR12","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1007\/s00259-022-05787-9","volume":"49","author":"R Laudicella","year":"2022","unstructured":"Laudicella R, R\u00fcschoff JH, Ferraro DA, Brada MD, Hausmann D, Mebert I, et al. Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on MpMRI. Eur J Nucl Med Mol Imaging. 2022;49(11):3917\u201328.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"7352_CR13","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1007\/s00259-021-05501-1","volume":"48","author":"JH R\u00fcschoff","year":"2021","unstructured":"R\u00fcschoff JH, Ferraro DA, Muehlematter UJ, Laudicella R, Hermanns T, Rodewald AK, et al. What\u2019s behind (68)Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. Eur J Nucl Med Mol Imaging. 2021;48(12):4042\u201353.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7352_CR14","doi-asserted-by":"publisher","first-page":"683793","DOI":"10.3389\/fonc.2021.683793","volume":"11","author":"K Shen","year":"2021","unstructured":"Shen K, Liu B, Zhou X, Ji Y, Chen L, Wang Q, et al. The evolving role of (18)F-FDG PET\/CT in diagnosis and prognosis prediction in progressive prostate Cancer. Front Oncol. 2021;11:683793.","journal-title":"Front Oncol"},{"issue":"1","key":"7352_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12149-010-0424-4","volume":"25","author":"R Minamimoto","year":"2011","unstructured":"Minamimoto R, Uemura H, Sano F, Terao H, Nagashima Y, Yamanaka S, et al. The potential of FDG-PET\/CT for detecting prostate cancer in patients with an elevated serum PSA level. Ann Nucl Med. 2011;25(1):21\u20137.","journal-title":"Ann Nucl Med"},{"issue":"8","key":"7352_CR16","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1007\/s00261-015-0520-y","volume":"40","author":"AM Brown","year":"2015","unstructured":"Brown AM, Lindenberg ML, Sankineni S, Shih JH, Johnson LM, Pruthy S, et al. Does focal incidental 18F-FDG PET\/CT uptake in the prostate have significance? Abdom Imaging. 2015;40(8):3222\u20139.","journal-title":"Abdom Imaging"},{"issue":"6","key":"7352_CR17","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.euf.2018.03.008","volume":"5","author":"E Lavall\u00e9e","year":"2019","unstructured":"Lavall\u00e9e E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, et al. Increased prostate Cancer glucose metabolism detected by (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography in localised Gleason 8\u201310 prostate cancers identifies very High-risk patients for early recurrence and resistance to castration. Eur Urol Focus. 2019;5(6):998\u20131006.","journal-title":"Eur Urol Focus"},{"issue":"3","key":"7352_CR18","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","volume":"39","author":"AA Fitzgerald","year":"2020","unstructured":"Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39(3):783\u2013803.","journal-title":"Cancer Metastasis Rev"},{"issue":"5\u20136","key":"7352_CR19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/prca.201300095","volume":"8","author":"EJ Hamson","year":"2014","unstructured":"Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteom Clin Appl. 2014;8(5\u20136):454\u201363.","journal-title":"Proteom Clin Appl"},{"issue":"2","key":"7352_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2967\/jnumed.120.244806","volume":"62","author":"A Altmann","year":"2021","unstructured":"Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J Nucl Med. 2021;62(2):160\u20137.","journal-title":"J Nucl Med"},{"issue":"3","key":"7352_CR21","doi-asserted-by":"publisher","first-page":"e0116683","DOI":"10.1371\/journal.pone.0116683","volume":"10","author":"F Liu","year":"2015","unstructured":"Liu F, Qi L, Liu B, Liu J, Zhang H, Che D, et al. Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. PLoS ONE. 2015;10(3):e0116683.","journal-title":"PLoS ONE"},{"issue":"7","key":"7352_CR22","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2967\/jnumed.121.262426","volume":"63","author":"CE Mona","year":"2022","unstructured":"Mona CE, Benz MR, Hikmat F, Grogan TR, Lueckerath K, Razmaria A, et al. Correlation of (68)Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: interim analysis of a prospective translational exploratory study. J Nucl Med. 2022;63(7):1021\u20136.","journal-title":"J Nucl Med"},{"issue":"8","key":"7352_CR23","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2967\/jnumed.123.265471","volume":"64","author":"G Wass","year":"2023","unstructured":"Wass G, Clifford K, Subramaniam RM. Evaluation of the diagnostic accuracy of FAPI PET\/CT in oncologic studies: systematic review and metaanalysis. J Nucl Med. 2023;64(8):1218\u201324.","journal-title":"J Nucl Med"},{"key":"7352_CR24","doi-asserted-by":"crossref","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244\u201352.","DOI":"10.1097\/PAS.0000000000000530"},{"key":"7352_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.nucmedbio.2022.04.010","volume":"110\u2013111","author":"M Nader","year":"2022","unstructured":"Nader M, Valla DF, Vriamont C, Masset J, Pacelli A, Herrmann K, et al. [(68)Ga]\/[(90)Y]FAPI-46: automated production and analytical validation of a theranostic pair. Nucl Med Biol. 2022;110\u2013111:37\u201344.","journal-title":"Nucl Med Biol"},{"issue":"10","key":"7352_CR26","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/s00259-021-05266-7","volume":"48","author":"J Ferdinandus","year":"2021","unstructured":"Ferdinandus J, Kessler L, Hirmas N, Trajkovic-Arsic M, Hamacher R, Umutlu L, et al. Equivalent tumor detection for early and late FAPI-46 PET acquisition. Eur J Nucl Med Mol Imaging. 2021;48(10):3221\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"7352_CR27","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/snmmi procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"7352_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"7352_CR29","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.2967\/jnumed.116.172627","volume":"57","author":"WP Fendler","year":"2016","unstructured":"Fendler WP, Schmidt DF, Wenter V, Thierfelder KM, Zach C, Stief C, et al. 68Ga-PSMA PET\/CT detects the location and extent of primary prostate Cancer. J Nucl Med. 2016;57(11):1720\u20135.","journal-title":"J Nucl Med"},{"issue":"1","key":"7352_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital Organs-Part B: prostate and bladder tumours. Eur Urol. 2016;70(1):106\u201319.","journal-title":"Eur Urol"},{"issue":"1","key":"7352_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00259-021-05423-y","volume":"49","author":"C Kesch","year":"2021","unstructured":"Kesch C, Yirga L, Dendl K, Handke A, Darr C, Krafft U, et al. High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics. Eur J Nucl Med Mol Imaging. 2021;49(1):385\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"18","key":"7352_CR32","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1158\/1078-0432.CCR-20-1358","volume":"26","author":"HM Hintz","year":"2020","unstructured":"Hintz HM, Gallant JP, Vander Griend DJ, Coleman IM, Nelson PS, LeBeau AM. Imaging fibroblast activation protein alpha improves diagnosis of metastatic prostate Cancer with positron emission tomography. Clin Cancer Res. 2020;26(18):4882\u201391.","journal-title":"Clin Cancer Res"},{"key":"7352_CR33","doi-asserted-by":"crossref","unstructured":"Vlachostergios PJ, Karathanasis A, Tzortzis V. Expression of fibroblast activation protein is enriched in neuroendocrine prostate cancer and predicts worse survival. Genes (Basel). 2022;13(1):135.","DOI":"10.3390\/genes13010135"},{"issue":"12","key":"7352_CR34","first-page":"1952","volume":"65","author":"RR Huang","year":"2024","unstructured":"Huang RR, Zuo C, Mona CE, Holzgreve A, Morrissey C, Nelson PS, et al. FAP and PSMA expression by immunohistochemistry and PET imaging in Castration-Resistant prostate cancer: A translational pilot study. J Nucl Med. 2024;65(12):1952\u20138.","journal-title":"J Nucl Med"},{"issue":"8","key":"7352_CR35","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2967\/jnumed.119.236786","volume":"61","author":"C Meyer","year":"2020","unstructured":"Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, et al. Radiation dosimetry and biodistribution of (68)Ga-FAPI-46 PET imaging in Cancer patients. J Nucl Med. 2020;61(8):1171\u20137.","journal-title":"J Nucl Med"},{"issue":"13","key":"7352_CR36","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s00259-021-05307-1","volume":"48","author":"FL Giesel","year":"2021","unstructured":"Giesel FL, Kratochwil C, Schlittenhardt J, Dendl K, Eiber M, Staudinger F, et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET\/CT in cancer patients. Eur J Nucl Med Mol Imaging. 2021;48(13):4377\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7352_CR37","doi-asserted-by":"publisher","first-page":"737827","DOI":"10.3389\/fonc.2021.737827","volume":"11","author":"J Wu","year":"2021","unstructured":"Wu J, Wang Y, Liao T, Rao Z, Gong W, Ou L, et al. Comparison of the relative diagnostic performance of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG PET\/CT for the detection of bone metastasis in patients with different cancers. Front Oncol. 2021;11:737827.","journal-title":"Front Oncol"},{"issue":"3","key":"7352_CR38","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2967\/jnumed.123.266652","volume":"65","author":"N Hirmas","year":"2024","unstructured":"Hirmas N, Hamacher R, Sraieb M, Kessler L, Pabst KM, Barbato F, et al. Diagnostic accuracy of (68)Ga-FAPI versus (18)F-FDG PET in patients with various malignancies. J Nucl Med. 2024;65(3):372\u20138.","journal-title":"J Nucl Med"},{"issue":"5","key":"7352_CR39","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2967\/jnumed.122.264689","volume":"64","author":"N Hirmas","year":"2023","unstructured":"Hirmas N, Hamacher R, Sraieb M, Ingenwerth M, Kessler L, Pabst KM, et al. Fibroblast-Activation protein PET and histopathology in a Single-Center database of 324 patients and 21 tumor entities. J Nucl Med. 2023;64(5):711\u20136.","journal-title":"J Nucl Med"},{"issue":"6","key":"7352_CR40","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of Cancer. J Nucl Med. 2019;60(6):801\u20135.","journal-title":"J Nucl Med"},{"key":"7352_CR41","doi-asserted-by":"crossref","unstructured":"Watanabe M, Fendler WP, Grafe H, Hirmas N, Hamacher R, Lanzafame H, et al. Head-to-head comparison of (68) Ga-FAPI-46 PET\/CT, (18)F-FDG PET\/CT, and contrast-enhanced CT for the detection of various tumors. Ann Nucl Med.2025;39(3)255\u201365.","DOI":"10.1007\/s12149-024-01993-7"},{"issue":"1","key":"7352_CR42","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.lungcan.2007.08.036","volume":"60","author":"N Al-Sarraf","year":"2008","unstructured":"Al-Sarraf N, Gately K, Lucey J, Wilson L, McGovern E, Young V. Lymph node staging by means of positron emission tomography is less accurate in non-small cell lung cancer patients with enlarged lymph nodes: analysis of 1,145 lymph nodes. Lung Cancer. 2008;60(1):62\u20138.","journal-title":"Lung Cancer"},{"issue":"1","key":"7352_CR43","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1097\/RLU.0000000000003837","volume":"47","author":"EG Isik","year":"2022","unstructured":"Isik EG, Has-Simsek D, Sanli O, Sanli Y, Kuyumcu S. Fibroblast activation Protein-Targeted PET imaging of metastatic Castration-Resistant prostate Cancer compared with 68Ga-PSMA and 18F-FDG PET\/CT. Clin Nucl Med. 2022;47(1):e54\u20135.","journal-title":"Clin Nucl Med"},{"issue":"8","key":"7352_CR44","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1007\/s00259-019-04623-x","volume":"47","author":"F Khreish","year":"2020","unstructured":"Khreish F, Rosar F, Kratochwil C, Giesel FL, Haberkorn U, Ezziddin S. Positive FAPI-PET\/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative\/FDG-positive disease. Eur J Nucl Med Mol Imaging. 2020;47(8):2040\u20131.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7352_CR45","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12149-021-01702-8","volume":"36","author":"K Kessel","year":"2022","unstructured":"Kessel K, Seifert R, Weckesser M, Boegemann M, Huss S, Kratochwil C, et al. Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging. Ann Nucl Med. 2022;36(3):293\u2013301.","journal-title":"Ann Nucl Med"},{"issue":"1","key":"7352_CR46","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00259-024-06891-8","volume":"52","author":"KM Pabst","year":"2024","unstructured":"Pabst KM, Mei R, L\u00fcckerath K, Hadaschik BA, Kesch C, Rawitzer J, et al. Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [(68)Ga]Ga-\/[(18)F]F-PSMA-11\/-1007, [(68)Ga]Ga-FAPI-46 and 2-[(18)F]FDG PET\/CT: a pilot study. Eur J Nucl Med Mol Imaging. 2024;52(1):342\u201353.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07352-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07352-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07352-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:03:49Z","timestamp":1762329829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07352-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":46,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["7352"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07352-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The local ethics committee (University Hospital Essen Ethic Committee) approved this retrospective study (Permission Numbers: 22-10706-BO) and waived the need for study-specific consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"BH reports Consulting or Advisory role for Lightpoint medical, Janssen, Bayer, Abx, Astellas, Merck, Amgen, MSD, Novartis, BMS, Onkowissen, POINT Biopharma, Pfizer, Ipsen, Accord Healthcare, Telix; Travel support from AstraZeneca, Bristol- Myers Squibb, Janssen, Bayer, and Ipsen; Research Funding from Janssen, Novartis and BMS, all outside of the submitted work. WPF reports fees from SOFIE Bioscience (research funding), Janssen (consultant, speaker), Calyx (consultant, image review), Bayer (consultant, speaker, research funding), Novartis (speaker, consultant), Telix (speaker), GE Health- care (speaker, consultant), Eczac\u0131ba\u015f\u0131 Monrol (speaker), Abx (speaker), Amgen (speaker), Urotrials (speaker) outside of the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}